# SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma

> **NCT03589222** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **PETHEMA Foundation** · enrollment: 62 (estimated)

## Conditions studied

- Refractory Multiple Myeloma

## Interventions

- **DRUG:** Selinexor
- **DRUG:** Daratumumab
- **DRUG:** Bortezomib
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT03589222
- **Lead sponsor:** PETHEMA Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-07-15
- **Primary completion:** 2026-08
- **Final completion:** 2026-08
- **Target enrollment:** 62 (ESTIMATED)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03589222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03589222, "SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03589222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*